Anti-HSV-1/HHV-1 gD Polyclonal Antibody

Catalog No.

PVV21401

Species reactivity

Human herpesvirus 1 (strain 17) (HHV-1) (Human herpes simplex virus 1)

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant HSV-1/HHV-1 gD (Pro48-Val311).

Target

gD, Envelope glycoprotein D

Purification

Antigen affinity purification.

Accession

Q69091

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity., PMID:40354699

A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing., PMID:40328740

Analysis of the Interaction Between the Attenuated HSV-1 Strain M6 and Macrophages Indicates Its Potential as an Effective Vaccine Immunogen., PMID:40143320

Herpes simplex virus 1 envelope glycoprotein C shields glycoprotein D to protect virions from entry-blocking antibodies., PMID:40135897

Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy., PMID:40007004

Improving antibody-mediated protection against HSV infection by eliminating interactions with the viral Fc receptor gE/gI., PMID:39605495

Immunogenicity and protective efficacy of a recombinant lactococcus lactis vaccine against HSV-1 infection., PMID:39252072

Herpes Simplex Virus 1 Envelope Glycoprotein C Shields Glycoprotein D to Protect Virions from Entry-Blocking Antibodies., PMID:39229192

Human Antibodies against Herpes Simplex Virus 2 Glycoprotein G Do Not Neutralize but Mediate Antibody-Dependent Cellular Cytotoxicity., PMID:38804308

Selection, activity, and nuclease stabilization of cross-neutralizing DNA aptamers targeting HSV-1 and HSV-2., PMID:37925791

OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment., PMID:37554264

A self-binding immune complex vaccine elicits strong neutralizing responses against herpes simplex virus in mice., PMID:37205110

Multiple Sites on Glycoprotein H (gH) Functionally Interact with the gB Fusion Protein to Promote Fusion during Herpes Simplex Virus (HSV) Entry., PMID:36629412

Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity., PMID:36357700

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma., PMID:35991754

A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D., PMID:35341808

Nectin-1 and Non-muscle Myosin Heavy Chain-IIB: Major Mediators of Herpes Simplex Virus-1 Entry Into Corneal Nerves., PMID:35295302

Hygiene Hypothesis Indicators and Prevalence of Antinuclear Antibodies in US Adolescents., PMID:35154106

Antiviral CD19+CD27+ Memory B Cells Are Associated with Protection from Recurrent Asymptomatic Ocular Herpesvirus Infection., PMID:34985998

Preventive Vaccination with Mesenchymal Stem Cells Protects Mice from Lethal Infection Caused by Herpes Simplex Virus 1., PMID:34931092

A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity., PMID:34417304

Antibodies Elicited in Response to a Single Cycle Glycoprotein D Deletion Viral Vaccine Candidate Bind C1q and Activate Complement Mediated Neutralization and Cytolysis., PMID:34209320

[Preventive Vaccination with Mesenchymal Stem Cells Protects Mice from Lethal Infection Caused by Herpes Simplex Virus 1]., PMID:34097682

Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine., PMID:33718970

Contributions of the Four Essential Entry Glycoproteins to HSV-1 Tropism and the Selection of Entry Routes., PMID:33653890

Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs., PMID:33627393

Enhanced Immune Responses and Protective Immunity to Zika Virus Induced by a DNA Vaccine Encoding a Chimeric NS1 Fused With Type 1 Herpes Virus gD Protein., PMID:35047887

Characterizing Epitope Binding Regions of Entire Antibody Panels by Combining Experimental and Computational Analysis of Antibody: Antigen Binding Competition., PMID:32796656

Localization of the Interaction Site of Herpes Simplex Virus Glycoprotein D (gD) on the Membrane Fusion Regulator, gH/gL., PMID:32759318

An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection., PMID:32716975

Induction of Rod-Shaped Structures by Herpes Simplex Virus Glycoprotein I., PMID:32581097

Vaccination Route as a Determinant of Protective Antibody Responses against Herpes Simplex Virus., PMID:32516944

Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity., PMID:32411398

HSV-1 infection and pathogenesis in the tree shrew eye following corneal inoculation., PMID:32301037

A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus., PMID:32295919

Alphaherpesvirus gB Homologs Are Targeted to Extracellular Vesicles, but They Differentially Affect MHC Class II Molecules., PMID:32290097

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies., PMID:32042851

Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization., PMID:31826995

Engineering HSV-1 Vectors for Gene Therapy., PMID:31617173

Differential Requirements for gE, gI, and UL16 among Herpes Simplex Virus 1 Syncytial Variants Suggest Unique Modes of Dysregulating the Mechanism of Cell-to-Cell Spread., PMID:31092572

Surface Plasmon Resonance Reveals Direct Binding of Herpes Simplex Virus Glycoproteins gH/gL to gD and Locates a gH/gL Binding Site on gD., PMID:31092568

Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1., PMID:30903291

Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects., PMID:30867302

Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes., PMID:30787156

[Mesenchymal stem cells enhance immune response and protect mice against lethal herpes viral infection.]., PMID:30641021

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation., PMID:30541787

Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins., PMID:30502324

Role of Microvesicles in the Spread of Herpes Simplex Virus 1 in Oligodendrocytic Cells., PMID:29514899

Immunization with dendritic cell-based DNA vaccine pRSC-NLDC145.gD-IL21 protects mice against herpes simplex virus keratitis., PMID:29370719

The potential of currently unavailable herpes virus vaccines., PMID:29313728

Document Download

Anti-HSV-1/HHV-1 gD Polyclonal Antibody.pdf